UK life sciences backing for budget that 'reiterates' investment promises

22 November 2017

While many in the UK life sciences sector have looked on with concern as Brexit-backing Conservatives have pushed the nation towards exiting the European Union (EU) without even agreeing a deal with the trade bloc, the government’s promises over the past year for funding for science and health have been widely welcomed by the industry.

Again, the reaction was positive on Wednesday when Chancellor Philip Hammond announced the 2017 budget, with several of his announcements bringing potential benefits for pharma and biotech, along with small companies and patients.

"Today's budget reiterates that the government recognizes our industry can be a driving force behind long-term sustainable economic growth"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK